LQDA
Liquidia Corporation
November 4, 2026 · intraday
- Rarity
- 1.76
- Peak move
- +17.20%
- Float cap
- $3.0B
Still running — rarity and peak move can only rise from here.
Liquidia Corporation is a biopharmaceutical company focused on respiratory and vascular diseases such as pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. It commercializes YUTREPIA, an inhaled dry powder treprostinil, in the United States and shares profit from Sandoz's generic treprostinil injection. It also develops L606 and calls on U.S. healthcare providers involved in treatment, distribution, and reimbursement.
Where do you see this going?
no votes yetVote to see the split.
What we found
no events · 0 from SEC or newswire · 0 timed with the moveNothing found.We searched SEC filings, the newswires and the open web across the three days around this move and found no public information that explains it.